The expression of programmed death ligand 1 (PD-L1) on tumor cells, tumor mutation burden (TMB), and high-frequency microsatellite instability (MSI-high) have been reported as biomarkers for the efficacy of anti-PD-1/PD-L1 antibodies. Here, PDCD1 is linked to neoplasm.